Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: A.J. Mullen who wrote (10203)	1/29/2004 3:18:59 PM
From: Biomaven	Read Replies (1) of 52153

easy to circumvent with generic components Except if they have a use patent for the combo (like POZN), or one or both of the components are under patent (SEPR Norvasc ICE and the ARB blockers are both under patent). Perocet - part of the reason for the combination is that it makes misuse harder - I think that straight immediate-release oxycodone (as distinct from time release oxycontin) may not even be approved in the US. If you take too much of the combination product in a day you perhaps get killed by acetaminophen poisoning (which is OK with the powers that be) rather than by an opiate overdose (not OK). <g> Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next